Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
4.610
+0.210 (4.77%)
Feb 5, 2026, 4:00 PM EST - Market closed
Molecular Partners AG Market Cap
Molecular Partners AG has a market cap or net worth of $171.4 million as of February 6, 2026. Its market cap has decreased by -11.32% in one year.
Market Cap
171.40M
Enterprise Value
39.00M
1-Year Change
-11.32%
Ranking
Category
Stock Price
$4.61
Market Cap Chart
Since the IPO on February 21, 2018, Molecular Partners AG's market cap has decreased from $595.47M to $171.40M, a decrease of -71.22%. That is a compound annual growth rate of -14.48%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 5, 2026 | 171.40M | 7.04% |
| Dec 30, 2025 | 160.13M | -2.96% |
| Dec 30, 2024 | 165.01M | 22.94% |
| Dec 29, 2023 | 134.22M | -38.09% |
| Dec 30, 2022 | 216.81M | -65.56% |
| Dec 30, 2021 | 629.47M | -8.03% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Feb 21, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Sol-Gel Technologies | 180.24M |
| NeOnc Technologies Holdings | 179.94M |
| Opus Genetics | 177.93M |
| Sagimet Biosciences | 176.92M |
| Milestone Pharmaceuticals | 174.72M |
| Humacyte | 171.03M |
| Prelude Therapeutics | 166.44M |
| C4 Therapeutics | 165.72M |